HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.

Christophe RODRIGUEZ, C Soulie, AG Marcelin, V Calvez, D Descamps, C Charpentier, P Flandre, P Recordon-Pinson, P Bellecave, Jean-Michel PAWLOTSKY, B Masquelier,

PLoS One. 11/06/2015;10(6) : e0127816 10.1371/journal.pone.0127816.

Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study.

Christophe HEZODE, GM Hirschfield, W Ghesquiere, W Sievert, M Rodriguez-Torres, SD Shafran, PJ Thuluvath, HA Tatum, I Waked, G Esmat, EJ Lawitz, VK Rustgi, S Pol, N Weis, PJ Pockros, M Bourliere, L Serfaty, JM Vierling, MW Fried, O Weiland, MR Brunetto, GT Everson, S Zeuzem, PY Kwo, M Sulkowski, N Brau, D Hernandez, F McPhee, M Wind-Rotolo, Z Liu, S Noviello, EA Hughes, PD Yin, S Schnittman,

Gut. 01/06/2015;64(6) : 948-956 10.1136/gutjnl-2014-307498 30/07/2014

Human hepatic stellate cells are not permissive for hepatitis C virus entry and replication.

A Florimond, P Chouteau, Patrice BRUSCELLA, J Le Seyec, E Merour, Nazim AHNOU, A Mallat, S Lotersztajn, Jean-Michel PAWLOTSKY,

Gut. 01/06/2015;64(6) : 957-965 10.1136/gutjnl-2013-305634. 25/07/2014

Low cross-neutralization of hepatitis C correlates with liver disease in immunocompromized patients.

G Maurin, B Halgand, Patrice BRUSCELLA, J Fresquet, JC Duclos-Vallee, AM Roque-Afonso, FL Cosset, D Samuel, D Lavillette, Cyrille FERAY,

AIDS. 01/06/2015;29(9) : 1025-33 10.1097/QAD.0000000000000651.

Bile duct adenoma should not be designated as a reactive process.

A Pujals, ES Zafrani, Julien CALDERARO,

Pathol Int 01/06/2015;65(6) : 338 10.1111/pin.12273. 02/03/2015

Response

P Soyer, B Taouli, B Guiu, DM Koh, Alain LUCIANI, R Manfredi, V Vilgrain, C Hoeffel, M Kanematsu, E Vicaut,

Radiology 01/06/2015;275(3) : 933-934 .

Sarcopenia Impacts on Short- and Long-term Results of Hepatectomy for Hepatocellular Carcinoma

T Voron, L Tselikas, D Pietrasz, F Pigneur, A Laurent, P Compagnon, C Salloum, Alain LUCIANI, D Azoulay,

Ann Surg 01/06/2015;261(6) : 1173-1183 10.1097/SLA.0000000000000743.

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.

AJ Muir, F Poordad, J Lalezari, G Everson, GJ Dore, R Herring, A Sheikh, P Kwo, Christophe HEZODE, PJ Pockros, A Tran, J Yozviak, N Reau, A Ramji, K Stuart, AJ Thompson, J Vierling, B Freilich, J Cooper, W Ghesquiere, R Yang, F McPhee, EA Hughes, ES Swenson, PD Yin,

Java 05/05/2015;313(17) : 1736-1744 10.1001/jama.2015.3868.

Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas

Giuliana AMADDEO, Q Cao, Y Ladeiro, S Imbeaud, JC Nault, D Jaoui, Y Gaston Mathe, C Laurent, A Laurent, P Bioulac-Sage, Julien CALDERARO, J Zucman-Rossi,

Gut. 01/05/2015;64(5) : 820-829 10.1136/gutjnl-2013-306228. 09/06/2014

Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.

Slim FOURATI, C Charpentier, C Amiel, L Morand-Joubert, S Reigadas, MA Trabaud, C Delaugerre, F Nicot, A Rodallec, A Maillard, A Mirand, H Jeulin, B Montes, F Barin, D Bettinger, H Le Guillou-Guillemette, S Vallet, A Signori-Schmuck, D Descamps, V Calvez, P Flandre, P Marcellin,

J Antimicrob Chemother 01/05/2015;70(5) : 1507-1512 10.1093/jac/dku535. 03/01/2015